Abstract: The invention provides methods of inhibiting the growth or metastasis of a cancer in a mammal by inhibiting a Ral GTPase in the mammal. The invention also provides small molecule inhibitors of Ral GTPases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds of the invention, and methods of using the same.

Abstract: Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p,R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods ace provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.

Abstract: Selective small molecule regulators of GIRK potassium channels are provided, which are effective in treatment of post-traumatic stress disorder and other medical conditions.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a thiopyrimidinone structure which function as inhibitors of ALDH protein, and their use as therapeutics for the treatment of cancer and other diseases.

Abstract: The present disclosure concerns synthesis, anion binding features, liquid-liquid extraction of salts, and anti-corrosion character of aryl-triazole bicyclic macrocycles of Formula (I) and related compounds:

Abstract: Apparatus and methods for driving a circulatory assist device with motive power from a fluid motor. In one example a parallel plate Tesla-type of motor extracts power from the circulatory system of a biological unit to drive a non-positive displacement pump and increase blood pressure in the biological unit.

Abstract: The present invention provides methods and materials useful delivering liquids, including liquids comprising nucleic acid molecules into cells. In particular, the present invention provides methods for delivering saline solution, exogenous compositions, and isolated vectors to kidney cells, using the renal vein as a guide and under hydrodynamic pressure. The delivery methods and materials herein are useful to research, prognose, ameliorate symptoms of kidney injury, and treat kidney pathologies.

Abstract: A motor includes: a stator having a plurality of electromagnets and a plurality of rolling elements arranged around the electromagnets; and a rotor having a plurality of rotor traction components arranged to engage the plurality of rolling elements; and a control circuit. The plurality of rolling elements are arranged relative to the plurality of rotor traction components to form a gap between the plurality of rolling elements and the plurality of rotor traction components. The control circuit is configured to activate the plurality of electromagnets to cause the rotor to pivot about a pivot point defined in a spherical bearing and change the gap such that the rotor compresses against the stator and the plurality of rolling elements and the plurality of rotor traction components translate the compression into tangential thrust and rotation of the rotor.

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of a condition/disease associated with insufficient quantity and/or quality of hematopoietic stem cells (HSCs) and differentiated blood cells thereof. Embodiments include compositions and methods for treating the condition/disease, comprising the step of providing to a subject at least one therapeutically effective dose of a composition disclosed herein. Other embodiments include methods for generating and/or collecting hematopoietic stem cells from a subject.

Abstract: Described herein are biomimetic Janus particles useful as artificial antigen presenting cells capable of activating T cells in vitro. “Bull's eye” ligand patterns mimicking either the native or reverse organization of the T cell immunological synapse are provided on the surface of nano- or micro-sized particles. Methods for activating T cells in vitro using biomimetic Janus particles described herein are also provided. T cells activated by the biomimetic Janus particles can be used in adoptive immunotherapies for treating cancer, tolerance induction in autoimmune disease, autologous immune enhancement therapy, and viral infection immunotherapy. Also described herein are methods for producing a biomimetic Janus particle.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: Antimicrobial compositions having bactericidal activity are described. Also described is a method of treating bacterial infections using compositions comprising antimicrobial peptides or variants thereof.

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistence to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

Abstract: The present disclosure relates generally to methods and compositions useful in cell and tissue biology and therapeutics. In particular, an in vitro method for differentiating pluripotent stem cells into KDR+NCAM+APLNR+ mesoderm cells and/or SSEA5?KDR+NCAM+APLNR+ mesoderm cells is provided. The disclosed mesoderm cells may be used to generate blood vessels in vivo and/or further differentiated in vitro into endothelial colony forming cell-like cells (ECFC-like cells). Purified human cell populations of KDR+NCAM+APLNR+ mesoderm cells and ECFC-like cells are provided. Test agent screening and therapeutic methods for using the cell populations of the present disclosure are provided.

Abstract: Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitor patients treated with acamprosate and to screen potentially therapeutic compounds.

Abstract: [[(2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylidene]-N,N-diethylpentanamide] (APX2009) and (2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronapthalen-2-yl)methylidene]-N-methoxypentanamide] (APX2014) for inhibiting ocular diseases are disclosed herein.

Abstract: Compositions including the combination of cremastranone analogs and anti-angiogenic agents and the use of the compositions for targeting ocular angiogenesis such as seen in neovascular eye diseases are disclosed.

Abstract: Methods of using serum glucocorticoid induced kinase 1 (SGK1) inhibitors for reducing the development of diseases related to salt and water balance, and in particular, hydrocephalus and/or hypertension, are disclosed herein. Particularly, the present disclosure is directed to the use of SGK1 inhibitors to inhibit transepithelial ion transport, such as in one embodiment, in the choroid plexus of a subject, thereby reducing cerebrospinal fluid (CSF) production or, alternatively, in another embodiment, to inhibit transepithelial sodium transport in the kidney collecting duct thereby reducing sodium reabsorption into the blood.

Abstract: An electric motor is provided, comprising: a first magnetic component, a second magnetic component, and a circuit configured to electromagnetically activate at least one of the first magnetic component and the second magnetic component. The electromagnetic activation causes a change in a gap between the first magnetic component and the second magnetic component, the change in the gap resulting in rotation of at least one of the first magnetic component and the second magnetic component.

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.